W.R. Berkley Corp’s Ibere Pharmaceuticals IBER Stock Holding History

W.R. Berkley Corp’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-69,176	Closed	-$698K	–	333
2022 Q4	$698K	Buy	69,176 +400	+0.6%	+$4K	0.04%	278
2022 Q3	$682K	Hold	68,776	–	–	0.03%	416
2022 Q2	$675K	Hold	68,776	–	–	0.03%	428
2022 Q1	$675K	Hold	68,776	–	–	0.03%	432
2021 Q4	$666K	Hold	68,776	–	–	0.04%	424
2021 Q3	$666K	Hold	68,776	–	–	0.04%	318
2021 Q2	$666K	Buy	+68,776	New	+$669K	0.07%	220

W.R. Berkley Corp's IBER Position: Q1 2023 in Review

W.R. Berkley Corp sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 69,176 shares — an estimated $698K sold.

W.R. Berkley Corp first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $698K in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

W.R. Berkley Corp reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
W.R. Berkley Corp sold 69,176 Ibere Pharmaceuticals shares in Q1 2023, an estimated $698K.
W.R. Berkley Corp first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
W.R. Berkley Corp's Ibere Pharmaceuticals position peaked at $698K in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on W.R. Berkley Corp's 13F filing for Q1 2023, filed 15 May 2023.